Fig. 2From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapyPositive proportion of seven biomarkers in HGSC and CCC patients. CCC patients expressed higher level of HER2 and BRCA1 than HGSC patients (12.6% vs 2.7%, 45.7% vs 27.4%, P = 0.006, 0.007 respectively, Chi-squared test)Back to article page